Specifically, the anti-proliferative effects of CDK4/6 inhibitors on both tumor cells and Tregs appear to be associated with reduced activity of DNA methyltransferase 1, that is encoded by the E2F target gene DNMT1 (29). The gene discussed is DNMT1; the disease is neoplasm.